Two novel epilepsy-linked mutations leading to a loss of function of LGI1

Arch Neurol. 2007 Feb;64(2):217-22. doi: 10.1001/archneur.64.2.217.

Abstract

Background: Mutations in the leucine-rich, glioma-inactivated 1 (LGI1) gene have been implicated in autosomal dominant lateral temporal epilepsy.

Objective: To describe the clinical and genetic findings in 2 families with autosomal dominant lateral temporal epilepsy and the functional consequences of 2 novel mutations in LGI1.

Design: Clinical, genetic, and functional investigations.

Setting: University hospital. Patients Two French families with autosomal dominant lateral temporal epilepsy. Main Outcome Measure Mutation analysis.

Results: Two novel disease-linked mutations, p.Leu232Pro and c.431 + 1G>A, were identified in LGI1. We demonstrated that the c.431 + 1G>A mutation causes the deletion of exons 3 and 4 of the LGI1 transcript and showed that the p.Leu232Pro mutation dramatically decreases secretion of the mutant protein by mammalian cells.

Conclusion: Our data indicate that LGI1 is a secreted protein and suggest that LGI1-related epilepsy results from a loss of function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blotting, Western / methods
  • DNA Mutational Analysis
  • Epilepsy / genetics*
  • Exons
  • Family Health
  • Female
  • Genetic Linkage / genetics
  • Humans
  • Intracellular Signaling Peptides and Proteins
  • Leucine / genetics
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Proline / genetics
  • Proteins / genetics*
  • Proteins / metabolism
  • RNA, Messenger / biosynthesis
  • Reverse Transcriptase Polymerase Chain Reaction / methods
  • Severity of Illness Index

Substances

  • Intracellular Signaling Peptides and Proteins
  • LGI1 protein, human
  • Proteins
  • RNA, Messenger
  • Proline
  • Leucine